As of June 30, 2026, the Company has assigned its goodwill in three reporting units, Generics and Other, Brands, and Rare Disease reporting units. There have been no events or changes in circumstances that would have reduced the fair value of the reporting units below their carrying value during the three and six months ended June 30, 2026, and 2025, respectively, and as a result, no impairment charges have been recognized.


	June 30, 2026						December 31, 2025						Remaining Weighted Average Amortization Period (1)
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Definite-Lived Intangible Assets:
Acquired ANDAs intangible assets	$	214,417	$	(158,199)	$	56,218	$	214,260	$	(147,511)	$	66,749	3.3 years
NDAs and product rights	679,804		(294,946)		384,858		673,554		(271,818)		401,736		9.8 years
Marketing and distribution rights	17,157		(16,676)		481		17,157		(16,195)		962		0.5 years
Customer relationships	24,900		(16,600)		8,300		24,900		(14,821)		10,079		2.3 years
Total Intangible Assets, net	$	936,278	$	(486,421)	$	449,857	$	929,871	$	(450,345)	$	479,526	8.8 years

Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that these assets might be impaired.

For the six months ended June 30, 2026, approximately $6.3 million of acquired definite-lived intangible assets consisting of product rights, patents, know-how, and trade secrets were capitalized pursuant to the Patent Purchase Agreement between Nuray Chemicals Private Limited (“Nuray”) and the Company.

Amortization expense for definite-lived intangibles was $17.4 million and $36.1 million for the three and six months ended June 30, 2026, respectively. Amortization expense for definite-lived intangibles was $21.1 million and $41.8 million for the three and six months ended June 30, 2025, respectively.

During the year ended December 31, 2025, $15.8 million was reclassified from indefinite-lived In-Process Research & Development (“IPR&D”) to definite-lived NDAs and product rights related to the commercialization of certain products, and will be amortized over ten years. As of June 30, 2026 and December 31, 2025 there was no IPR&D on the unaudited condensed consolidated balance sheets.